CD19 mRNA quantification improves rituximab treatment-to-target approach: A proof of concept study

Journal of Neuroimmunology

Volumn 277, Issue 1-2, 2014, Pages 127-133

  Marnetto, Fabiana ^a   Granieri, Letizia ^a   Valentino, Paola ^a   Capobianco, Marco ^a   Pautasso, Marisa ^b   Bertolotto, Antonio ^a  

^a SAN LUIGI GONZAGA UNIVERSITY HOSPITAL   (Italy)

^b SAN LUIGI GONZAGA HOSPITAL   (Italy)

Author keywords

CD19+ B cells; Flow cytometry; Neuromyelitis optica spectrum disorders; Pre amplification real time PCR; Rituximab re treatment

Indexed keywords

CD19 ANTIGEN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE 1; IMMUNOGLOBULIN; MESSENGER RNA; RITUXIMAB; UNCLASSIFIED DRUG; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ANTIGEN DETECTION; ARTICLE; B LYMPHOCYTE; BLOOD SAMPLING; CASC 3 GENE; CASE REPORT; CD19 GENE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GAPDH GENE; GENE AMPLIFICATION; GENETIC STABILITY; HOUSEKEEPING GENE; HPRT 1 GENE; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; MYELOOPTIC NEUROPATHY; PERSONALIZED MEDICINE; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY; RETREATMENT; SENSITIVITY ANALYSIS; DRUG EFFECTS; GENETICS; MALE; METABOLISM; NEUROMYELITIS OPTICA; REFERENCE VALUE;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD19; ANTIRHEUMATIC AGENTS; B-LYMPHOCYTES; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; NEUROMYELITIS OPTICA; REFERENCE VALUES; RNA, MESSENGER;

EID: 84919330033     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2014.09.008     Document Type: Article

References (11)

1. Capobianco M., Malucchi S., di Sapio A., Gilli F., Sala A., Bottero R., Marnetto F., Doriguzzi Bozzo C., Bertolotto A. Variable responses to rituximab treatment in neuromyelitis optica (Devic's disease). Neurol. Sci. 2007, 28:209-211.
2. Edwards J.C., Cambridge G. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat. Rev. Immunol. 2006, 6:394-403.
3. Feldman R.J., Razzaque A.A. Relevance of Rituximab Therapy in Pemphigus Vulgaris. Analysis of Current Data and the Immunologic Basis for Its Observed Responses. Expert. Rev. Clin. Immunol. 2011, 7:529-541.
4. Greenberg B.M., Graves D., Remington G., Hardeman P., Mann M., Karandikar N., Stuve O., Monson N., Frohman E. Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success. Mult. Scler. 2012, 18:1022-1026.
5. Kim S.H., Kim W., Li X.F., Jung I.J., Kim H.J. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2years. Arch. Neurol. 2011, 68:1412-1420. (Nov).
6. Kim S.H., Huh S.Y., Lee S.J., Joung A., Kim H.J. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. JAMA Neurol. 2013, 70:1110-1117.
7. McKeon A., Pittock S. Individualized rituximab treatment for neuromyelitis Optica spectrum disorders. JAMA Neurol. 2013, 70:103-104.
8. Noutsias M., Rohde M., Block A., Klippert K., Lettau O., Blunert K., Hummel M., Kühl U., Lehmkuh l.H., Hetzer R., Rauch U., Poller W., Pauschinger M., Schultheiss H.P., Volk H.D., Kotsch K. Preamplification techniques for real-time RT-PCR analyses of endomyocardial biopsies. BMC Mol. Biol. 2008, 9:3. (14).
9. Pellkofer H.L., Krumbholz M., Berthele A., Hemmer B., Gerdes L.A., Havla J., Bittner R., Canis M., Meinl E., Hohlfeld R., Kuempfel T. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology 2011, 76:1310-1315.
10. van Herwaarden N., van der Maas A., Jansen T.L., Dutmer E.A., Hartkamp A., van Riel P.L., Kievit W., van den Bemt B.J., den Broeder A.A. Can response duration after the first rituximab treatment be used in timing of rituximab re-treatment?. Scand. J. Rheumatol. 2013, 42:251-252.
11. Wingerchuk D.M., Lennon V.A., Pittock S.J., Lucchinetti C.F., Weinshenker B.G. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006, 23:1485-1489.